Kintara Therapeutics Updates on Corporate Developments and REM-001 Study

SAN DIEGO, Sept. 11, 2024 -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical firm specializing in new therapies for solid tumors, has provided updates on its corporate status and the REM-001 clinical study.

Corporate Developments
In April 2024, Kintara entered into a merger agreement with TuHURA Biosciences, Inc. According to the agreement, Kayak Mergeco, Inc., a subsidiary of Kintara, will merge into TuHURA, making TuHURA a wholly-owned subsidiary of Kintara. Post-merger, Kintara's existing stockholders will own about 5.45% of the combined entity's common stock, including contingent value rights (CVRs). These CVRs will grant stockholders additional shares upon the enrollment of ten patients in the REM-001 study by December 31, 2025.

A Special Meeting of Stockholders is planned for September 20, 2024, to seek approval for the merger. The meeting will be held virtually, and shareholders need to register by September 19, 2024, to vote. Those who held Kintara shares on August 14, 2024, are eligible to vote.

Stockholders prior to the merger's completion will receive CVRs, irrespective of their stockholder status on the Record Date. Voting can be done via phone or internet, with specific instructions provided depending on the shareholder's broker or service platform.

REM-001 Clinical Study Progress
As of September 10, 2024, the REM-001 study focusing on cutaneous metastatic breast cancer (CMBC) has enrolled four out of the necessary ten patients to evaluate safety and determine the appropriate dose for Phase 3. Several other candidates have been identified at Kintara's clinical sites, including Memorial Sloan Kettering Cancer Center and Montefiore Medical Center.

No safety issues related to treatment have been identified so far, and the evaluation of the appropriate Phase 3 dose continues. CMBC is an area with high unmet medical needs, as current therapies are neither approved nor effective. REM-001 aims to provide a new treatment option for these patients. Most of the study's costs are covered by a $2.0 million SBIR grant from the National Institutes of Health.

The continuation of the REM-001 study and the broader business operations of Kintara are contingent upon the successful completion of the merger with TuHURA. Without the merger, Kintara may face financial challenges that could push it towards bankruptcy. Therefore, Kintara strongly urges its stockholders to vote in favor of the merger at the upcoming Special Meeting.

About TuHURA Biosciences, Inc.
TuHURA is at the Phase 3 registration stage in immuno-oncology, working on new technologies to overcome cancer immunotherapy resistance. Its lead candidate, IFx-2.0, is designed to counter primary resistance to checkpoint inhibitors. TuHURA plans to start a Phase 3 trial of IFx-2.0 as an adjunctive therapy to Keytruda® for treating advanced or metastatic Merkel Cell Carcinoma.

TuHURA is also progressing in developing bi-functional antibody-drug conjugates (ADCs) using its Delta receptor technology. These ADCs target Myeloid Derived Suppressor Cells to mitigate their immune-suppressing effects in the tumor microenvironment, thereby preventing T cell exhaustion and acquired resistance to therapies.

About Kintara Therapeutics, Inc.
San Diego-based Kintara focuses on developing novel cancer therapies for patients with unmet medical needs. Its primary program, REM-001 Therapy, targets cutaneous metastatic breast cancer. The therapy uses a photodynamic treatment platform that combines a laser light source, a light delivery device, and the REM-001 drug. This therapy has been evaluated in four Phase 2/3 trials, achieving an 80% complete response rate in CMBC lesions and maintaining a robust safety profile across approximately 1,100 patients.

Kintara's mission is to develop therapies that address significant unmet medical needs with reduced risk development programs.